Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, May 5, 2026 to discuss first quarter 2026 financial results and provide a business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocugen (NASDAQ: OCGN) will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, May 5, 2026 to discuss first quarter 2026 financial results and provide a business update. A pre-market earnings announcement will be issued the same day.
Dial-in numbers: U.S. (800) 715-9871; International (646) 307-1963; Conference ID: 4973685. The webcast and replay will be available on the Ocugen investor site events section.
Details
News Market Reaction – OCGN
On Apr 29, the day this news came out, OCGN closed 1.20% above the previous close.
Data tracked by StockTitan Argus for the Apr 29 session.
Key Figures
- Current price
- $1.66
- Pre‑announcement trading level
- Price vs 52-week high
- -39.08%
- Relative to 52-week high of $2.725
- Price vs 52-week low
- 159.38%
- Above 52-week low of $0.64
- 200-day MA
- $1.47
- OCGN trading above this level pre-earnings
- Conference time
- 8:30 a.m. ET
- Q1 2026 business update and earnings call on May 5, 2026
- U.S. dial-in
- (800) 715-9871
- Access number for the May 5, 2026 call
- International dial-in
- (646) 307-1963
- Access number for non-U.S. callers
- Conference ID
- 4973685
- Identifier for the May 5, 2026 conference call
Previous Conferences,earnings Reports
-
Announced Mar 4, 2026 call for Q4 and full-year 2025 results.
-
Set Nov 5, 2025 Q3 2025 earnings call with pre-market release.
-
Announced Aug 1, 2025 Q2 2025 earnings conference call.
-
Scheduled May 9, 2025 call on Q1 2025 results and updates.
-
Planned Mar 5, 2025 call on Q4 and full-year 2024 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2026 financial results and provide a business update at 8:30 a.m. ET on Tuesday, May 5, 2026.
Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:
Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4973685
Webcast: Available on the events section of the Ocugen investor site
A replay of the call and archived webcast will be available on the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.